Testing the Addition of KRT-232 (AMG 232) to Usual Chemotherapy for Relapsed Multiple Myeloma
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Teva Branded Pharmaceutical Products R&D, Inc.
Teva Branded Pharmaceutical Products R&D, Inc.
Incyte Corporation
Incyte Corporation
Incyte Corporation
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Mayo Clinic
Scripps Translational Science Institute
Hackensack Meridian Health
Roswell Park Cancer Institute
Cartesian Therapeutics
Gilead Sciences
University of Maryland, Baltimore
Janssen Research & Development, LLC
Roswell Park Cancer Institute
GlaxoSmithKline
Hackensack Meridian Health
Takeda
Medical College of Wisconsin
Wake Forest University Health Sciences
University of California, San Francisco
Cartesian Therapeutics
Altor BioScience
Columbia University
Jazz Pharmaceuticals
Altor BioScience
University of California, San Francisco
Stemline Therapeutics, Inc.
Poseida Therapeutics, Inc.
University of Nebraska
GlaxoSmithKline
Oncopeptides AB
OHSU Knight Cancer Institute
GlaxoSmithKline
Weill Medical College of Cornell University
Gilead Sciences
Hoosier Cancer Research Network
Ohio State University Comprehensive Cancer Center
University of Nebraska
Hackensack Meridian Health
Massachusetts General Hospital
Rutgers, The State University of New Jersey
University of Pennsylvania
Beth Israel Deaconess Medical Center
Oncopeptides AB
Weill Medical College of Cornell University
Amgen
H. Lee Moffitt Cancer Center and Research Institute
Albert Einstein College of Medicine